Table 1.
The association between FZD2 expression and clinical-pathological characteristics in breast cancers
| Expression of FZD2 | |||
|---|---|---|---|
| Factors | Low (N = 71) | High (N = 34) | P-value |
| Age (years) | |||
| ≤ 50 | 35 | 17 | 1 |
| > 50 | 36 | 17 | |
| Tumor size (cm) | |||
| < 2.5 | 31 | 22 | 0.060 |
| ≥ 2.5 | 40 | 12 | |
| ER status | |||
| (+) | 35 | 23 | 0.095 |
| (−) | 36 | 11 | |
| PR status | |||
| (+) | 44 | 20 | 0.832 |
| (−) | 27 | 14 | |
| Her-2 status | |||
| (+) | 22 | 13 | 0.511 |
| (−) | 49 | 21 | |
| Ki-67 status (%) | |||
| ≤ 20% | 24 | 10 | 0.824 |
| > 20% | 47 | 24 | |
| Pathological grading | |||
| I–II | 51 | 23 | 0.655 |
| III | 20 | 11 | |
| TNM stage | |||
| I–II | 57 | 18 | 0.006* |
| III–IV | 14 | 16 | |
| Lymph-node metastasis | |||
| pN0 | 54 | 18 | 0.024* |
| pN+ | 17 | 16 | |
| Organ metastasis | |||
| No | 65 | 15 | 0.000* |
| Yes | 6 | 19 | |
ER estrogen receptor, FZD2 frizzled class receptor 2, Her-2 human epidermal growth factor receptor 2, PR progesterone receptor
* P < .05 was considered statistically significant